Title |
Pro: Are we ready to translate Alzheimer's disease modifying therapies to people with Down syndrome?
|
---|---|
Published in |
Alzheimer's Research & Therapy, September 2014
|
DOI | 10.1186/s13195-014-0060-7 |
Pubmed ID | |
Authors |
Michael S Rafii |
Abstract |
Down Syndrome (DS) is caused by trisomy of chromosome 21, which includes the gene for the amyloid precursor protein (APP) and leads to overproduction of beta-amyloid. Clinical-pathological studies indicate that individuals with DS begin demonstrating Alzheimer's disease (AD) pathology during adolescence and that 100% exhibit such changes by age 40. Individuals with DS therefore represent a highly enriched population for AD. Additionally, owing to their baseline intellectual disability, people with DS represent a more vulnerable group of individuals as compared with other populations. Given the recent developments in AD biomarkers, combined with the prospect of achieving greater efficacy with earlier therapeutic intervention, it is logical to include adults with DS in prevention trials for AD. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 33% |
Spain | 1 | 33% |
United States | 1 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 34 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 8 | 24% |
Student > Bachelor | 6 | 18% |
Student > Ph. D. Student | 4 | 12% |
Student > Master | 3 | 9% |
Other | 2 | 6% |
Other | 5 | 15% |
Unknown | 6 | 18% |
Readers by discipline | Count | As % |
---|---|---|
Psychology | 5 | 15% |
Medicine and Dentistry | 5 | 15% |
Agricultural and Biological Sciences | 4 | 12% |
Biochemistry, Genetics and Molecular Biology | 4 | 12% |
Neuroscience | 2 | 6% |
Other | 4 | 12% |
Unknown | 10 | 29% |